FC
KRYS icon

FORA Capital’s Krystal Biotech KRYS Stock Holding History

FORA Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,732
Closed -$1.48M – 470
2026
Q1 		$1.48M Buy
5,732
+3,620
+171% +$963K 0.11% 189
2025
Q4 		$521K Buy
+2,112
New +$445K 0.06% 292
2024
Q2 		– Sell
-5,936
Closed -$1.06M – 461
2024
Q1 		$1.06M Buy
+5,936
New +$825K 0.09% 235
2023
Q3 		– Sell
-8,427
Closed -$989K – 528
2023
Q2 		$989K Buy
+8,427
New +$860K 0.14% 163

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FORA Capital's KRYS Position: Q2 2026 in Review

FORA Capital sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 5,732 shares — an estimated $1.48M sold.

FORA Capital first reported a position in KRYS in Q2 2023 and held it in 4 quarters. The position peaked at $1.48M in Q1 2026. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • FORA Capital reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • FORA Capital sold 5,732 Krystal Biotech shares in Q2 2026, an estimated $1.48M.
  • FORA Capital first reported a position in Krystal Biotech in Q2 2023 and held it in 4 quarters.
  • FORA Capital's Krystal Biotech position peaked at $1.48M in Q1 2026.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.